OSI Pharmaceuticals, Inc.
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Published in Medical Letter on the CDC and FDA, August 23rd, 2009
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC) when used as single agent, maintenance therapy in patients who did not progress following first-line treatment with platinum-based chemotherapy. As previously announced, the safety results in this study were consistent with what has been seen previously and there were no new or unexpected safety signals. Overall survival was a key secondary endpoint of the study and these new data were presented today at the 13th World Conference on Lung Cancer being held in San...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Adverse Drug Reactions
Tufts University publishes research in adverse drug reactions - Angiogenesis
Researchers at University of Erlangen publish new data on angiogenesis - Cancer
Data from A. Kazi and colleagues advance knowledge in cancer - Cancer
Project Zero Delay Accelerates Drug's Path to Clinical Trial - Cancer Vaccines
Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer - Health Insurance
Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
